(E)-Ethyl 3-(4-Bromo-3-Fluorophenyl)Acrylate
|
- $175 - $1786
- Product name: (E)-Ethyl 3-(4-Bromo-3-Fluorophenyl)Acrylate
- CAS: 1173119-94-2
- MF: C11H10BrFO2
- MW: 273.1
- EINECS:
- MDL Number:MFCD22124741
- Synonyms:(E)-Ethyl 3-(4-Bromo-3-Fluorophenyl)Acrylate;2-Propenoic acid, 3-(4-bromo-3-fluorophenyl)-, ethyl ester, (2E)-;Ethyl (E)-3-(4-Bromo-3-fluorophenyl)prop-2-enoate;Ethyl (E)-3-(4-bromo-3-fluorophenyl)acrylate
4 prices
Selected condition：
Brand
- AK Scientific
- Crysdot
- TRC
Package
- 50mg
- 250mg
- 1g
- 5g
- ManufacturerAK Scientific
- Product number4198AQ
- Product descriptionethyl(E)-3-(4-bromo-3-fluorophenyl)prop-2-enoate
- Packaging250mg
- Price$354.8
- Updated2021-12-16
- Buy
- ManufacturerCrysdot
- Product numberCD12176514
- Product description(E)-Ethyl3-(4-bromo-3-fluorophenyl)acrylate 95+%
- Packaging1g
- Price$594
- Updated2021-12-16
- Buy
- ManufacturerCrysdot
- Product numberCD12176514
- Product description(E)-Ethyl3-(4-bromo-3-fluorophenyl)acrylate 95+%
- Packaging5g
- Price$1786
- Updated2021-12-16
- Buy
- ManufacturerTRC
- Product numberE900248
- Product descriptionEthyl(E)-3-(4-Bromo-3-fluorophenyl)prop-2-enoate
- Packaging50mg
- Price$175
- Updated2021-12-16
- Buy
| Manufacturer | Product number | Product description | Packaging | Price | Updated | Buy |
|---|---|---|---|---|---|---|
| AK Scientific | 4198AQ | ethyl(E)-3-(4-bromo-3-fluorophenyl)prop-2-enoate | 250mg | $354.8 | 2021-12-16 | Buy |
| Crysdot | CD12176514 | (E)-Ethyl3-(4-bromo-3-fluorophenyl)acrylate 95+% | 1g | $594 | 2021-12-16 | Buy |
| Crysdot | CD12176514 | (E)-Ethyl3-(4-bromo-3-fluorophenyl)acrylate 95+% | 5g | $1786 | 2021-12-16 | Buy |
| TRC | E900248 | Ethyl(E)-3-(4-Bromo-3-fluorophenyl)prop-2-enoate | 50mg | $175 | 2021-12-16 | Buy |
Properties
Boiling point :321.4±27.0 °C(Predicted)
Density :1.458±0.06 g/cm3(Predicted)
Density :1.458±0.06 g/cm3(Predicted)
Safety Information
| Symbol(GHS): | ||||||||
|---|---|---|---|---|---|---|---|---|
| Signal word: | ||||||||
| Hazard statements: |
|
|||||||
| Precautionary statements: |
|